Drug Profile


Alternative Names: IMO-B project; OXI 104

Latest Information Update: 26 May 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OXiGENE
  • Developer Active Biotech; Genzyme Oncology; Harvard Medical School; OXiGENE; University of Texas System
  • Class Benzamides; Chemosensitisers; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Inflammatory bowel diseases; Solid tumours

Most Recent Events

  • 15 May 2003 Discontinued - Preclinical for Inflammatory bowel disease in Sweden (PO)
  • 07 May 2002 Declopramide has been licensed to Active Biotech AB for World-wide rights
  • 30 Apr 2002 Preclinical trials in Inflammatory bowel disease in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top